| Improve wakefulness in adults with excessive sleepiness associated with narcolepsy, obstructive sleep apnea, or shift work disorder (label). View labelExact | Narcolepsy or OSA: 200 mg once daily in the morning (label). | Wakefulness-promoting agent used for excessive sleepiness in narcolepsy, obstructive sleep apnea, and shift work disorder; Schedule IV with important rash/hypersensitivity warnings and clinically relevant CYP3A4 induction and CYP2C19 inhibition interactions. | CYP3A4, CYP2C19 | Steady-state mean 15 h | No | — | - Rash and hypersensitivity monitoring, especially during the first 1–5 weeks (label).
- Mood and psychiatric symptom monitoring (anxiety, agitation, mania/psychosis) (label/clinical).
- Sleep disruption monitoring (insomnia, timing effects) (clinical).
- Drug interaction review (CYP3A induction; CYP2C19 inhibition), including contraception counseling (label).
| No | 2025-12-30 |
|---|
methylphenidateAdjunctive therapyBrands: RITALIN, CONCERTA, DAYTRANA, METADATE CD, QUILLIVANT XR | Attention-deficit/hyperactivity disorder (ADHD); narcolepsy (product-dependent). View labelExact | Adults (typical pattern): low morning dose with weekly titration based on benefit and tolerability; immediate-release products often need a noon dose, while extended-release products are typically once daily.
Typical adult total daily dosing varies by product. For extended-release (Concerta): 18–72 mg/day. Labeled maxima vary by product and delivery system; dose escalation that worsens sleep is typically avoided. A pretreatment evaluation including cardiac history, family history of sudden death, and assessment for tics/Tourette syndrome is recommended before initiation. If no improvement is observed within one month at appropriate doses, the medication should be discontinued. | Central nervous system stimulant; inhibits dopamine and norepinephrine reuptake (DAT/NET). | CES1 (carboxylesterase) to ritalinic acid | Single-dose mean 3 h | No | — | - Baseline and periodic blood pressure and heart rate (more often during titration).
- Appetite and weight are tracked; meal and nutrition counseling is common if weight loss occurs.
- Sleep onset, total sleep time, and evening rebound are monitored; timing/formulation changes are often tried first.
- Anxiety, agitation, mood elevation, or hallucinations are monitored; stopping and reassessing is often considered if symptoms emerge.
- Misuse/diversion risk is reviewed, and safe storage counseling is commonly documented.
| No | 2026-03-31 |
|---|
| Attention-deficit/hyperactivity disorder (ADHD); binge eating disorder in adults (product-dependent). View labelExact | Usually once daily in the morning; afternoon/evening dosing is typically avoided due to insomnia risk.
Typical adult starting dose is 30 mg once daily, with titration in 10–20 mg steps (often weekly) based on response and tolerability. | Prodrug stimulant converted to dextroamphetamine; increases dopamine and norepinephrine signaling. | Enzymatic hydrolysis (blood) to dextroamphetamine | Single-dose mean 11 h | No | — | - Baseline and periodic blood pressure and heart rate (more often during titration).
- Appetite and weight/BMI are tracked; nutrition and meal timing are revisited if weight loss occurs.
- Sleep onset and duration are monitored; timing adjustments are often tried before adding sedatives.
- Anxiety, agitation, mood elevation, or hallucinations are monitored; if concerning symptoms emerge, discontinuation and reassessment are common.
- Misuse/diversion risk is reviewed and safe storage counseling is documented.
| No | 2026-02-20 |
|---|
| Attention-deficit/hyperactivity disorder (ADHD); narcolepsy (product-dependent). View labelExact | Doses are typically started low and titrated gradually based on functional improvement and tolerability. Immediate-release products often require BID dosing; extended-release products are typically once daily in the morning.
Typical adult total daily dosing often falls in the 5–40 mg/day range, but labeled maxima vary by product and indication. | CNS stimulant; increases dopamine and norepinephrine signaling via release and reuptake inhibition. | CYP2D6 (partial), Oxidative deamination and other non-CYP pathways | Single-dose mean 11 h; Single-dose range 9–14 h | No | — | - Baseline and periodic blood pressure and heart rate (more often during titration).
- Track appetite and weight/BMI; revisit nutrition and meal timing if weight loss occurs.
- Monitor sleep onset and duration; adjust timing/formulation before adding sedatives.
- Monitor for anxiety, agitation, mood elevation, or hallucinations; stop/reassess if symptoms emerge.
- Review misuse/diversion risk and document safe storage counseling.
| No | 2026-02-20 |
|---|